Video

Dr. Hill Discusses Combinations in MCL

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma (MCL).

There is a lot of interest in combining Bruton's tyrosine kinase inhibitors with other agents, says Hill, including ibrutinib (Imbruvica) plus venetoclax (Venclexta) and ibrutinib plus ixazomib (Ninlaro). Ixazomib is an oral proteasome inhibitor that has known activity in patients with MCL.

The ongoing phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax in patients with relapsed/refractory MCL. Individually, both agents have achieved response rates of 67% to 75% in this patient population.

Ibrutinib is also being combined with monoclonal antibodies, which Hill says could be an interesting treatment strategy for patients with MCL.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center